Jubilant Ingrevia Share Price Today (JUBLINGREA)
TODAY IN ONE LINE
Closed at ₹725.85 (−1%); delivery 65.1%. Market opens 9:15 IST. · as of 09:59 IST
With a market cap of ₹11,579.74 Cr., it trades at a P/E of 42.12. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Jubilant Ingrevia flags
Key strengths and potential risks.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 16.1% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 12.1% and Profit up 16.7%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
Red Flags
- ●Poor Capital ReturnsLow ROE of 9.5%
- ●FII SellingFII holding decreased by 1.00% QoQ
- ●Promoter Pledging DetectedPledge activity recorded on 18-Aug-2025 18:47
What changed recently?
Recent events, corporate actions, and announcements.
Jubilant Ingrevia Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Jubilant Ingrevia Limited, framed against the sector median so the premium or discount is obvious at a glance.
Jubilant Ingrevia Limited trades at a P/E of 42.12× and P/B of 3.74×.
Valuation
Profitability
Growth
Financial Health
Jubilant Ingrevia Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Jubilant Ingrevia Limited — derived from the live tape, not yesterday's close.
Jubilant Ingrevia Limited last traded at ₹725.85 with an intraday range of ₹723.95–₹741.75 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹725.85| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 772.68 | +46.83 | +6.45% |
| R3 | 754.88 | +29.03 | +4.00% |
| R2 | 748.32 | +22.47 | +3.10% |
| R1 | 737.08 | +11.23 | +1.55% |
| PIVOT | 730.52 | 4.67 | 0.64% |
| CURRENT | 725.85 | — | — |
| S1 | 719.28 | -6.57 | -0.90% |
| S2 | 712.72 | -13.13 | -1.81% |
| S3 | 701.48 | -24.37 | -3.36% |
| S4 | 683.68 | -42.17 | -5.81% |
JUBLINGREA is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹730–₹741.75
Trading Inside opening range
Jubilant Ingrevia Limited financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Jubilant Ingrevia Limited, switchable between annual and quarterly views, consolidated or standalone.
Jubilant Ingrevia Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹11,579.74 Cr. and reported EPS of ₹18.39.
| Period | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue from Operations | 684 | 4,949 | 4,773 | 4,136 | 4,178 | 4,388 |
| Other Income | 3 | 31 | 33 | 35 | 38 | 41 |
| Total Income | 687 | 4,981 | 4,806 | 4,171 | 4,215 | 4,429 |
| Cost of Goods Sold (COGS) | 370 | 2,794 | 2,582 | 2,143 | 2,107 | 2,295 |
| Gross Profit | 314 | 2,155 | 2,191 | 1,993 | 2,070 | 2,093 |
| +Operating Expenses | 197 | 1,323 | 1,644 | 1,572 | 1,551 | 1,526 |
| EBITDA | 117 | 832 | 547 | 421 | 519 | 567 |
| +Non-Operating Expenses | 16 | 154 | 144 | 189 | 213 | 212 |
| Profit Before Tax (PBT) | 77 | 709 | 437 | 268 | 344 | 370 |
| +Tax Expense | 23 | 232 | 129 | 85 | 92 | 92 |
| Total Profit for Period | 54 | 477 | 308 | 183 | 251 | 278 |
| Net Profit (Owner's PAT) | 54 | 477 | 308 | 183 | 251 | 278 |
| Earnings Per Share (EPS) | 3.41 | 29.93 | 19.31 | 11.48 | 15.77 | 17.45 |
| Diluted Shares Outstanding (Nos.) | 16 | 16 | 16 | 16 | 16 | 16 |
| +Additional Disclosures | 984 | 7,162 | 6,953 | 6,050 | 5,981 | 6,374 |
| Sales Growth % | — | 623.45 | -3.57 | -13.34 | 1.01 | 5.04 |
| YoY Sales Growth % | — | 623.45 | -3.57 | -13.34 | 1.01 | 5.04 |
| Material Cost % | 53 | 57 | 53 | 49 | 49 | 48 |
| Employee Cost % | 7 | 7 | 7 | 9 | 10 | 10 |
| Other Cost % | 22 | 20 | 27 | 29 | 27 | 25 |
| OPM % | 17 | 17 | 11 | 10 | 12 | 13 |
| Tax % | 30 | 33 | 30 | 32 | 27 | 25 |
| Profit Growth % | — | 776.95 | -35.50 | -40.52 | 37.33 | 10.65 |
| Gross Margin % | 45.92 | 43.55 | 45.91 | 48.19 | 49.56 | 47.70 |
| EBITDA Margin % | 17.12 | 16.81 | 11.46 | 10.18 | 12.43 | 12.92 |
| Interest Coverage Ratio | 12.97 | 22.90 | 19.69 | 5.41 | 6.50 | 7.97 |
| Ebit | 95 | 708 | 425 | 285 | 361 | 392 |
Jubilant Ingrevia segment analysis: revenue and profit mix.
Disclosed business segments at Jubilant Ingrevia with their share of revenue and profit, switchable between consolidated and standalone reporting.
Jubilant Ingrevia discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Jubilant Ingrevia Limited.
Our AI distills the core fundamental drivers supporting Jubilant Ingrevia Limited, the risks that threaten it, and the exact valuation or growth triggers that should make you re-evaluate.
Jubilant Ingrevia Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 16.7% YoY, demonstrating improving profitability momentum.
TTM revenue grew 12.1% YoY, showing consistent top-line expansion despite historical flatness.
Low debt-to-equity ratio of 0.0025 provides substantial financial flexibility for growth.
Operating cash flow of ₹97.08 Cr indicates healthy liquidity generation capacity.
Moderate promoter holding of 45.23% ensures stable governance and long-term alignment.
Key Risks.
Latest quarterly EPS declined 12.6% QoQ from ₹4.75 to ₹4.40, showing significant volatility.
ROE of 9.51% and ROCE of 11.40% lag peer benchmarks substantially, limiting capital efficiency.
Operating margin of 9.01% trails peer median of 10.75%, constraining profitability.
Net margin of 6.64% TTM below peer average of 10.81%, indicating persistent cost pressures.
FII holdings eased from 10.19% to 6.15% over nine quarters, signaling foreign investor caution.
Flip Conditions.
Trim if P/E re-rates above 55. The valuation cushion thins from there.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Income thesis breaks if the dividend is cut or yield falls below 0.35%.
Jubilant Ingrevia Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Jubilant Ingrevia Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Jubilant Ingrevia Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Jubilant Ingrevia Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Jubilant Ingrevia Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Jubilant Ingrevia Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Jubilant Ingrevia Limited stood at 65.1% of traded volume, against a 20-day average of 56.8%.
Jubilant Ingrevia announcements: results, concalls, ratings, M&A.
Filings Jubilant Ingrevia sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Jubilant Ingrevia files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 180 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Jubilant Ingrevia Limited has informed the Exchange about Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations,…
Trading Window
Jubilant Ingrevia Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Copy of Newspaper Publication
Jubilant Ingrevia Limited has informed the Exchange about Copy of Newspaper Publication
Investor Presentation
Jubilant Ingrevia Limited has informed the Exchange about Investor Presentation
Press Release
Jubilant Ingrevia Limited has informed the Exchange regarding a press release dated May 26, 2026, titled "Press release and presentation on the…
Investor decks & rating reports.
Jubilant Ingrevia dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Jubilant Ingrevia has declared, sequenced by announce and record date.
Jubilant Ingrevia corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Jubilant Ingrevia insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Jubilant Ingrevia as reported to SEBI — buying and selling signals from the people who know the business best.
Jubilant Ingrevia insider activity below tracks 51 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Jubilant Ingrevia Employees Welfare Trust | Insider | 23 Mar 2026 | buy | +10.0 K | ₹56.21 L | ₹562.09 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 23 Mar 2026 | buy | +10.0 K | ₹56.21 L | ₹562.09 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 23 Mar 2026 | buy | +10.0 K | ₹56.21 L | ₹562.09 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 23 Mar 2026 | buy | +10.0 K | ₹56.21 L | ₹562.09 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 23 Mar 2026 | buy | +10.0 K | ₹56.21 L | ₹562.09 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 20 Mar 2026 | buy | +25.0 K | ₹1.45 Cr. | ₹581.66 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 20 Mar 2026 | buy | +25.0 K | ₹1.45 Cr. | ₹581.66 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 20 Mar 2026 | buy | +25.0 K | ₹1.45 Cr. | ₹581.66 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 20 Mar 2026 | buy | +25.0 K | ₹1.45 Cr. | ₹581.66 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 19 Mar 2026 | buy | +50.0 K | ₹2.89 Cr. | ₹578.86 |
About Jubilant Ingrevia Limited: business, sector, key facts.
What Jubilant Ingrevia Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Jubilant Ingrevia Limited operates in the Specialty Chemicals industry under the Chemicals sector, listed as NSE: JUBLINGREA, BSE: 543271.
Jubilant Ingrevia Limited (formerly Jubilant LSI Limited) is a global life sciences company operating across India, the United States, Europe, and China. The company's core business centers on the development, manufacture, and supply of a diverse range of specialty chemicals, nutrition & health solutions, and chemical intermediates. This multifaceted approach allows them to serve a wide spectrum of industries.
Their Specialty Chemicals segment is a significant contributor, offering a comprehensive portfolio including bio-pyridine and -picolines, fine chemicals, agrochemicals, and custom development and manufacturing services. This segment also encompasses solutions for microbial control, highlighting a focus on both the development of specific chemical compounds and the provision of tailored solutions to meet specific customer needs.
The Nutrition & Health Solutions segment focuses on the production and supply of ingredients and solutions for both human and animal nutrition. This involves a range of products, from vitamins (such as Vitamin B3 and B4) and minerals to premixes, antioxidants, and other specialized nutritional components. The company's expertise extends to providing solutions for stress regulation and enhancing egg quality in animal feed, demonstrating a commitment to various market segments within the nutrition sector.
The Chemical Intermediates segment provides essential building blocks for various industries. Their offerings include acetyls, specialty ethanol, and a wide array of pyridine derivatives with diverse functional groups (cyano, acetyl, amino, halo, alkyl, and aldehyde). This segment emphasizes the supply of fundamental chemicals that form the basis for many downstream applications.
In addition to product offerings, Jubilant Ingrevia provides comprehensive services, including route design, process development, optimization, and scale-up for commercial manufacturing of intermediates. This integrated approach differentiates them by offering end-to-end solutions, supporting clients throughout the entire process from initial concept to large-scale production.
Jubilant Ingrevia serves a diverse client base across pharmaceutical, animal and human nutrition, agrochemical, personal and consumer care, and industrial sectors. Their broad product and service portfolio combined with their global reach establishes them as a significant player in the life sciences industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarti Industries (AARTIIND) Share PricePeer
- Aarti Surfactants (AARTISURF) Share PricePeer
- Archean Chemical Industries (ACI) Share PricePeer
- Aether Industries (AETHER) Share PricePeer
- Alkali Metals (ALKALI) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Jubilant Ingrevia Limited (JUBLINGREA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Jubilant Ingrevia Limited (JUBLINGREA)?
The current share price of Jubilant Ingrevia Limited (JUBLINGREA) is ₹725.85. Today, the stock has declined by ₹7.35 (1.00%), trading in a range of ₹723.95 to ₹741.75. The stock opened at ₹732.95 with a trading volume of 1,58,130 shares.
02Is Jubilant Ingrevia Limited stock a good investment for long-term?
Jubilant Ingrevia Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹11,579.74 crores, P/E ratio of 42.12, ROE of 9.51%, and ROCE of 11.40%. The dividend yield stands at 0.70%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Jubilant Ingrevia Limited stock?
The 52-week high price of Jubilant Ingrevia Limited (JUBLINGREA) is ₹851.8, while the 52-week low is ₹537.3. Currently trading at ₹725.85, the stock is 60.0% away from its 52-week low and 14.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Jubilant Ingrevia Limited stock at the current price?
Whether to buy Jubilant Ingrevia Limited stock at ₹725.85 depends on multiple factors. The stock is currently trading with a P/E ratio of 42.12 and P/B ratio of 3.74. Today's performance shows a loss of 1.00%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Jubilant Ingrevia Limited and when is the next dividend?
Jubilant Ingrevia Limited offers a dividend yield of 0.70%, which means for every ₹100 invested at the current price of ₹725.85, you can expect to receive approximately ₹0.70 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Jubilant Ingrevia Limited?
Jubilant Ingrevia Limited's key financial metrics include: P/E Ratio: 42.12, P/B Ratio: 3.74, ROE: 9.51%, ROCE: 11.40%, Dividend Yield: 0.70%, EPS: ₹18.39, Book Value: ₹197.83, and Debt-to-Equity: 0.00. The company's market cap stands at ₹11,579.74 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Jubilant Ingrevia Limited stock performing today in the market?
Jubilant Ingrevia Limited stock opened at ₹732.95 and is currently trading at ₹725.85, showing a decline of ₹7.35 (1.00%). The intraday high is ₹741.75 and low is ₹723.95. The trading volume stands at 1,58,130 shares, indicating moderate market participation today.
08What is the P/E ratio of Jubilant Ingrevia Limited and what does it indicate?
Jubilant Ingrevia Limited has a Price-to-Earnings (P/E) ratio of 42.12, which means investors are willing to pay ₹42.12 for every ₹1 of earnings. With an EPS of ₹18.39, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Jubilant Ingrevia Limited (JUBLINGREA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.